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ABSTRACT
Objective: Carbonic anhydrase 9 recognized by chimeric monoclonal antibody cG250 is overexpressed
on biliary cancers. The aim of this study was to determine the targeting of radiolabeled cG250 in patients
with biliary cancer to explore a potential role of radioimmunotherapy.
Methods: Three (3) patients received a diagnostic dose 111In-cG250, and images were acquired 2 hours
and 5 days after injection. Immediately after the last imaging session, 131I-cG250 was administered and
images were acquired after 2 hours and 5 days. Visual and quantitative analyses was performed and tu-
mor-to-background, tumor-to-normal liver-uptake ratios, and tumor uptake were calculated.
Results: Administration of 111In-cG250 in patients with biliary cancer did not reveal enhanced uptake
in the cancer lesions on whole-body scans. The scans obtained after the 131I-cG250 administration showed
slightly enhanced tumor uptake in 1 patient with cholangiocarcinoma stage II. In 2 patients with gall-
bladder carcinoma stage IV, neither 111In-cG250 nor 131I-cG250 showed targeting of known tumor le-
sions. Immunohistochemical analysis demonstrated CAIX expression in all 3 cases. There were no ad-
verse events related to radiolabeled cG250 administration.
Conclusions: 111In- or 131I-labeled cG250 is not suitable for biliary cancer targeting. Therefore, there
is no basis to develop radioimmunotherapy based on radiolabeled cG250 in biliary cancer.
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INTRODUCTION
Cancer of the biliary tract (cholangiocarcinoma
and gallbladder cancer) is a malignancy arising
from the epithelial cells of the intrahepatic and
extrahepatic bile ducts. Approximately 7480
cases of extrahepatic biliary tract cancer are di-
agnosed annually in the United States,1 two thirds
of which comprise gallbladder cancer. Biliary
cancer accounts for approximately 3% of all gas-
trointestinal malignancies, with a prevalence in
autopsy studies of 0.01–0.46 percent.2 Although
biliary cancer is a relatively rare malignancy, it
is associated with a high mortality rate, and as
such, represents an unmet clinical need. The poor
prognosis is most likely related to the advanced
stage at diagnosis, which is owing to the lack of
specific clinical signs and symptoms and to the
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anatomic position of the gallbladder. In the ma-
jority of patients, tumors are found incidentally
when undergoing surgical exploration for
cholelithiasis. Biliary cancer is diagnosed in
1%–2% of such cases.3
Monoclonal antibody (MoAb) G250 has been
the subject of investigation in renal-cell cancer
(RCC) for many years.4,5 This MoAb recognizes
carbonic anhydrase isotype IX (CAIX) expressed
on the majority of clear-cell–type RCCs.6,7 His-
tological studies have demonstrated expression of
the CAIX antigen on the epithelium of the bile
ducts.8 In vivo expression of the CAIX antigen
in this compartment is exemplified by the sat-
urable uptake of G250 antibody in the liver:
When a low-protein dose ( 2 mg) of G250 an-
tibody is administered, high liver uptake is ob-
served (mean, 3.4 percent injected dose [%ID]).
When higher protein doses ( 5 mg) are admin-
istered, uptake in the liver is reduced (mean, 2.1
%ID).9 Additionally, biliary tumors express
CAIX, and CAIX expression has been suggested
to be a potential biomarker for biliary cancer.9
The expression of CAIX in this noriously diffi-
cult tumor suggested that MoAb G250 might be
useful in the treatment of biliary cancer.
The aim of this study was to determine the tu-
mor-targeting potential of radiolabeled chimeric
monoclonal antibody cG250 in patients with bil-
iary cancer, preceding the development of a ra-
dioimmunotherapy (RIT) protocol. Furthermore,
iodine or metallic radiolabeled cG250 was stud-
ied to determine which radiolabel might be bet-
ter suited for biliary cancer targeting.
MATERIALS, PATIENTS, 
AND METHODS
Monoclonal Antibody cG250
The isolation and the immunohistochemical re-
activity of MoAb G250 have been described pre-
viously.10,11 To reduce the immunogenicity of the
antibody, a chimeric version has been devel-
oped.12 The reactivity of MoAb cG250 to normal
human tissues is restricted to the (upper) gas-
trointestinal mucosa (stomach, ileum, proximal,
and middle colon) and gastrointestinal-related
structures (intra- and extrahepatic biliary system,
pancreas).13,14 MoAb cG250 is reactive with the
CAIX antigen, which is expressed on the cell 
surface of the majority of the clear-cell–type
RCCs15,16 and in various other carcinomas (e.g.,
colon and squamous cell carcinomas).
Radiolabeling and Quality Control
The DTPA-cG250 conjugate was prepared, as de-
scribed previously.17 The cG250-DTPA conjugate
(5 mg, 1.0 mg/mL acetate buffer, pH 5.5) was ra-
diolabeled with 111InCl3 (Tyco Healthcare; Petten,
the Netherlands). The specific activity of the final
preparation was adjusted to 44.4 MBq 111In/mg
MoAb cG250 by adding unlabeled MoAb cG250.
MoAb cG250 was radioiodinated with 131I (MDS
Nordion; Fleurus, Belgium), according to the
IodoGen method, using a remote system, as de-
scribed previously.18,19 Radioiodinated cG250
was purified by AG1-XR resin filtration (Bio-Rad
Laboratories; Hercules, CA) in phosphate buffered
saline (PBS). Again, the specific activity of the fi-
nal preparation was adjusted to 44.4 MBq 131I/mg
MoAb cG250 by adding unlabeled antibody. The
radiochemical purity of each of the radiolabeled
cG250 preparations was determined by instant
thin-layer chromatography (ITLC) using ITLC sil-
ica gel strips (Gelman Sciences, Inc.; Ann Arbor,
MI), using 0.15 M citrate buffer (pH 5.0) as the
mobile phase, and always exceeded 95%. The im-
munoreactive fraction at infinitive antigen excess
of both radiolabeled cG250 preparations was de-
termined on freshly trypsinized SK-RC-52 RCC
cells, essentially as described by Lindmo and Bunn
with minor modifications.20,21 The immunoreac-
tive fraction of all preparations, used in these stud-
ies, exceeded 80%.
Patients
Patients with histological and/or cytological
proven advanced biliary cancer were eligible for
the study. Inclusion criteria included: interval be-
tween any anticancer therapy and cG250 admin-
istration of at least 4 weeks. Patients needed to
be at least 18 years of age, in female patients of
childbearing age, a pregnancy test had to be neg-
ative, Karnofsky score needed to be higher or
equal to 70%, hematological parameters in the
peripheral blood within normal limits, and liver
enzymes not exceeding five times of the upper
limit of normal, if liver metastases were present.
Patients with cardiac disease (New York Heart
Association Classification of 3 or 4), with unre-
lated serious illness (e.g., active infection), or a
life expectancy shorter than 4 months were ex-
cluded from this study.
This study was approved by the Institutional
Review Board of the Radboud University Nij-
megen Medical Centre (Nijmegen, the Nether-
lands). Prior to study entry, written, informed
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consent was obtained from all patients before
study entry.
Study Protocol
A CT of the chest and abdomen was obtained less
than 4 weeks prior to cG250 administration. Pa-
tients were injected intravenously with 222 MBq
(6 mCi) 111In-cG250 in 0.9% NaCl (5 mg pro-
tein; total volume, 10 mL) over a 5-minute pe-
riod. Vital signs were monitored up to 2 hours
after injection. After 2 hours and 5 days after in-
jection, anterior and posterior whole-body planar
images were recorded using a double-headed
gamma camera (E-cam, Siemens Inc.; Hoffman
Estates, IL) equipped with parallel-hole medium
energy collimators (scan speed 8 cm/minute and
4 cm/minute, respectively). An aliquot of the in-
jected dose was placed in the field of view. Sym-
metric 15% windows were used over both the
172- and 246-keV energy peaks. The data were
stored digitally in a 256  1024 matrix. Directly
after the recording of the 111In-cG250 images at
4 days p.i., the patient was intravenously (i.v.) in-
jected with 222 MBq (6 mCi) 131I-cG250 (5 mg
protein; total volume, 10 mL) over a 5-minute pe-
riod. Again, vital signs were monitored up to 2
hours after injection. Two (2) hours postinjection
(p.i.) and 4 days later, whole-body planar images
were recorded (high-energy collimators, sym-
metric 15% window over 364 keV, scan speed 5
and 4 cm/minutes, respectively) and stored digi-
tally in a 256  1024 matrix.
All whole-body scans were analyzed visually
and quantitatively. When the tumor was visual-
ized, regions of interest (ROI) were drawn over
liver and the biliary tumor.
Tumor-to-normal liver uptake ratios and tu-
mor-to-background for 111In-cG250 and 131I-
cG250 were calculated.
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Figure 1. (A) Computed tomography (CT)-scan slice
of abdomen of patient X showing a large tumor in seg-
ment 4 of the liver. (B) Scintigram of the abdomen of
the patient shown in (A) region 5 days after adminis-
tration of 222 MBq In111-cG250 showing a photopenic
lesion (arrow), as compared to the normal liver. (C)
Scintigram of the abdomen of patient X 5 days after ad-
ministration of 222 MBq I131-cG250 demonstrating min-
imal I131-cG250 accumulation at the edge of the known
tumor lesion (arrows).
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Blood samples were drawn up to 4 days after
injection of each radiolabeled antibody prepara-
tion to estimate plasma clearance of the radiola-
beled antibody preparations.
Immunohistochemistry
Tumor samples from included patients were col-
lected retrospectively from pathology archives and
processed for immunohistochemical analysis. Rep-
resentative slides were stained with M75, recog-
nizing CAIX using previously described methods.9
Briefly, slides were deparaffinized, rehydrated, mi-
crowave treated, and incubated with M75, washed,
incubated with peroxidase conjugated rabbit-anti-
mouse Ig (Dako A/S, Glostrup, Denmark), and 
developed using 33-diaminobenzidine tetrahy-
drochloride (DAB; Sigma, St. Louis, MO) as chro-
mogen, counterstained with hematoxylin, dehy-
drated, and mounted.
RESULTS
Three (3) patients (2 female, 1 male; age, 54–60
years) were included. Two (2) patients had stage
IV gallbladder carcinoma, and 1 patient had stage
II cholangiocarcinoma. One (1) patient with ex-
tensive disease underwent a cholecystectomy only,
while a large portion of tumor mass proved to be
nonresectable. The other 2 patients only had a bi-
opsy of the tumor. None of the patients received
any other therapy, such as chemotherapy, prior to
cG250 imaging, assuring that antigen expression
was not modified owing to systemic treatment.
Two (2) patients showed slightly elevated liver en-
zymes owing to hepatic involvement and com-
pression of the common bile duct. Administration
of the radiolabeled antibody was well tolerated by
all patients, and no clinical side-effects were ob-
served. No significant changes in blood pressure,
pulse rate, and body temperature were detected.
The initial plasma half-lives for both radiola-
beled cG250 of 111In-cG250 and 131I-cG250 were
45  28 hours and 43  23 hours, respectively.
Overall, t1/2 was 45  23 hours for both labeled
antibody preparations.
In only 1 of 3 patients (Fig. 1), a rim of the tu-
mor (stage II cholangiocarcinoma) could be dis-
tinguished from normal liver activity. However,
the tumor, as a whole, showed no significant an-
tibody uptake and was photopenic, as compared
to the normal liver (tumor-to-liver ratios of 0.4
for 111In-cG250 and 0.77 for 131I-cG250). In the
other 2 patients, neither 111In-cG250 nor 131I-
cG250 showed any accumulation in known tu-
mor lesions.
Immunohistochemical analyses revealed strong
CAIX expression in 2 tumor specimens and mod-
erate CAIX expression in the 3rd tumor specimen.
Tumors consisted of epithelial components in a
large field of connective tissue and/or large cysts
(Fig. 2). CAIX expression was comparable to
CAIX expression in normal larger bile ducts.
DISCUSSION
Although administration of radiolabeled cG250
was well tolerated without apparent clinical side-
effects, this study shows that in vivo expression
in biliary cancer is insufficient to delineate ma-
lignancies of the biliary tract, despite the docu-
mented presence of the G250 antigen on normal
bile-duct epithelium. In 2 of 3 patients, the tumor
was not visualized at all, and in the 3rd patient,
the tumor was visualized because the lesion was
photopenic, as compared to normal liver.
Additional single-photon emission computed
tomography (SPECT) might have improved the
readability of the images. However, this study
was designed as a therapeutic clinical trial in
which the imaging with low-dose 131I-cG250 and
111In-cG250 served as an indicator for sufficient
antigen expression in vivo, providing adequate tu-
mor-to-normal tissue ratios that would allow for
treatment with high-dose radiolabeled cG250. As
all patients had large tumor deposits that failed
to accumulate radiolabeled cG250 in vivo,
SPECT was not performed. Although SPECT
might have separated the tumors better from nor-
mal liver activity than the planar images, ade-
quate tumor-to-liver ratios that provided a thera-
peutic window for radioimmunotherapy would
not have been achieved. This finding is in sharp
contrast with the observations in patients with
RCC, in whom radiolabeled cG250 tumor uptake
proved to be among the highest reported for any
radiolabeled antibody.22 In RCC patients, 131I-
cG250 accumulates in both primary tumors and
metastases to allow accumulated delineation of
malignancy in, and in the vicinity of, the liver.23
As normal liver uptake of 111In-cG250 is approx-
imately three times higher than that of 131I-
cG250,24 111In-cG250 tumor uptake has to be high
and persistent, as compared to normal liver, to pro-
vide any window for imaging and/or therapy.
The organ distribution, as observed on the
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Figure 2. (A) Needle biopsy showing G250-positive cells in a field largely containing fibroblasts and supportive cells (50X
magnification). Immunomicrographs of archival tumor tissues stained for CAIX expression: (B) Biliary tumor (gallbladder car-
cinoma) with low expression of CAIX (400X magnification) and (C) Biliary tumor (gallbladder carcinoma) with large cysts,
demonstrating strong CAIX expression (50X magnification).
whole-body scans and the plasma clearance in
biliary cancer patients, closely resembled those
in RCC patients for both radiolabeled antibodies.
Thus, distinct differences in these parameters
cannot explain the lack of accumulation in bili-
ary cancer, as compared to RCC patients.
Both 111In-cG250 and 131I-cG250 provided
highly similar results in biliary cancer patients.
Thus, the apparent lack of tumor uptake cannot
be attributed to internalization and subsequent
degradation of the radionuclide-antibody com-
plex, as this would have resulted in a discrepancy
between the 111In (residualizing) and 131I (non-
residualizing) images (relatively high tumor up-
take on the 111In images, as compared to the 131I
images). This phenomenon played a role in RCC
patients, in whom 111In-cG250 showed generally
better targeting of malignancy than 131I-cG250.25
Although the initial administration of 5 mg of
111In-labeled cG250 might interfere with the tar-
geting of 5 mg of 131I-labeled cG250 4 days later,
various trials with cG250 have convincingly
demonstrated these doses do not interfere. For ex-
ample, the accumulation of two radioiodinated
cG250-preparations in primary RCC tumors was
identical when the 2 injections were given 4 days
apart.26 Moreover, 5 mg of cG250 antibody fol-
lowed by cG250 protein doses up to 25 mg did
not affect tumor accumulation in patients.27
Saarnio et al. showed that 57% of gall-blad-
der–invasive lesions and 78% of cholangiocellu-
lar malignant lesions expressed CAIX.28 To ex-
clude that the lack of tumor, accumulation was
owing to lack of CAIX expression; tumor tissues
of all 3 patients were analyzed by immunohisto-
chemistry. Strong CAIX expression was ob-
served in 2 specimens, and moderate to low ex-
pression in the 3rd specimen. In none of the pa-
tients could an appreciable accumulation of radi-
olabeled cG250 in tumor tissue could be demon-
strated, despite the presence of G250-positive
tumor cells. Importantly, tumor areas consisted
of large fields of stromal cells, with relatively few
tumor cells or consisted of large cysts. Thus, the
failure to adequately visualize these tumors is
probably owing to an unfavorable tumor:nontu-
mor ratio. Considering the former, the study was
prematurely terminated after 3 patients, because
it appeared that accumulation of radiolabeled
MoAb cG250 in biliary cancer was insufficient
to warrant successful development of a thera-
peutic approach.
CONCLUSIONS
This study shows that chimeric monoclonal anti-
body G250, whether labeled with 131I or 111In,
shows insufficient tumor targeting in patients with
biliary cancer, most likely owing to an intrinsic
unfavorable tumor:nontumor ratio within liver tis-
sue. Therefore, radioimmunotherapy of biliary
cancer with radiolabeled cG250 seems unjustified.
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